ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Position Lowered by Fmr LLC

FMR LLC reduced its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 11.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 4,378,819 shares of the company's stock after selling 541,541 shares during the period. FMR LLC owned about 6.21% of ORIC Pharmaceuticals worth $44,883,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ORIC. Hennion & Walsh Asset Management Inc. purchased a new stake in ORIC Pharmaceuticals in the 2nd quarter worth approximately $724,000. Bank of New York Mellon Corp grew its stake in shares of ORIC Pharmaceuticals by 62.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company's stock valued at $1,318,000 after buying an additional 71,394 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ORIC Pharmaceuticals by 162.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company's stock valued at $36,000 after buying an additional 3,188 shares during the period. Rhumbline Advisers grew its stake in shares of ORIC Pharmaceuticals by 53.7% during the 2nd quarter. Rhumbline Advisers now owns 92,702 shares of the company's stock valued at $655,000 after buying an additional 32,402 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of ORIC Pharmaceuticals by 8.3% during the 2nd quarter. Victory Capital Management Inc. now owns 95,850 shares of the company's stock valued at $678,000 after buying an additional 7,310 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ORIC shares. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Wedbush reissued an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Tuesday, November 12th. Wells Fargo & Company started coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They set an "overweight" rating and a $20.00 price objective for the company. Oppenheimer lowered their price objective on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus started coverage on shares of ORIC Pharmaceuticals in a research report on Friday, September 6th. They set a "buy" rating and a $20.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $18.29.

ORIC Pharmaceuticals Trading Up 3.6 %

ORIC stock traded up $0.34 during trading on Friday, reaching $9.90. The stock had a trading volume of 177,552 shares, compared to its average volume of 357,967. ORIC Pharmaceuticals, Inc. has a 1-year low of $6.33 and a 1-year high of $16.65. The company has a market capitalization of $698.64 million, a P/E ratio of -5.50 and a beta of 1.13. The firm has a fifty day moving average price of $9.47 and a 200 day moving average price of $9.36.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01). Sell-side analysts predict that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current year.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.